Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Avigen, Inc. (NasdaqNM:AVGN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug  8Earnings Announcement
Location
1301 Harbor Bay Parkway
Alameda, CA 94502
Phone: (510) 748-7150
Fax: (510) 748-7155
Email: paulson@avigen.com
Employees (last reported count): 82
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 25%
·Over the last 6 months:
 · 4 insider sells; 45.0K shares
  (0.9% of insider shares)
·Institutional: 32% (43% of float)
(100 institutions)
·Net Inst. Buying: 128.0K shares (+1.98%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Avigen Inc. is a leader in the development of gene therapy products for the treatment of inherited diseases. The Company is developing a broad-based proprietary gene delivery technology based on adeno-associated virus vector technology, known as AAV vectors, to deliver DNA into the cells of patients that are suffering from genetic diseases. AAV vectors are a relatively new system for gene therapy. The Company believes that AAV vectors can be used to deliver genes for the treatment of hemophilia, Gaucher disease, Parkinson's disease and beta-thalassemia.
More from Market Guide: Expanded Business Description

Financial Summary
Avigen, Inc. develops gene therapy products derived from adeno-associated virus for the treatment of inherited and acquired diseases. The products are designed for in vivo administration to achieve the production of therapeutic proteins within the body. For the fiscal year ended 6/30/01, revenues rose 100% to $116 thousand. Net loss increased 6% to $16 million. Revenues reflect increased grant revenues. Higher loss reflects increased research and development expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Philip Whitcome, Ph.D., 52
Chairman
$180K--  
John Monahan, Ph.D., 53
Pres, CEO
402K$416K
Thomas Paulson, 54
VP, Fin., CFO and Sec.
262K1.7M
Janice Castillo
VP, Regulatory Affairs
--  --  
Elliott Grossbard, M.D.
VP, Clinical Affairs
--  --  
Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:AVGNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$9.75 
Recent Price$14.77 
52-Week High
on 9-Nov-2000
$49.75 
Beta1.15 
Daily Volume (3-month avg)101.8K
Daily Volume (10-day avg)101.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-61.0%
52-Week Change
relative to S&P500
-47.7%
Share-Related Items
Market Capitalization$292.5M
Shares Outstanding19.8M
Float14.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$8.43 
Earnings (ttm)-$0.85 
Earnings (mrq)-$0.23 
Sales (ttm)$0.01 
Cash (mrq)$7.95 
Valuation Ratios
Price/Book (mrq)1.75 
Price/EarningsN/A 
Price/Sales (ttm)2,385.86 
Income Statements
Sales (ttm)$116.0K
EBITDA (ttm)-$23.7M
Income available to common (ttm)-$16.0M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsJune 30
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-11.62%
Return on Equity (ttm)-12.24%
Financial Strength
Current Ratio (mrq)67.73 
Debt/Equity (mrq)0.03 
Total Cash (mrq)$157.7M
Short Interest
As of 8-Aug-2001
Shares Short1.30M
Percent of Float8.7%
Shares Short
(Prior Month)
1.17M
Short Ratio16.87 
Daily Volume77.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.